Barr Pharmaceuticals

Barr Pharmaceuticals (NYSE-BRL) is a specialty pharmaceutical company primarily engaged in the development, manufacture and marketing of generic and proprietary prescription pharmaceuticals. The Company manufactures and distributes more than 100 different dosage forms and strengths of pharmaceutical products in core therapeutic categories, including oncology, female healthcare including hormone replacement and oral contraceptives, cardiovascular, anti-infective and psychotherapeutics. In addition, the Company has a proprietary, novel vaginal ring drug delivery system it is using to develop products intended to address a variety of female health issues and unmet medical needs.

On October 24, 2001, the Company merged with Duramed Pharmaceuticals, Inc. On June 6, 2002, the Company purchased certain assets of Enhance Pharmaceuticals, Inc., including a proprietary, novel, vaginal ring drug delivery system. The company is headquartered in Wood Cliff Lakes, NJ. Bruce Downey is the CEO.

The parent company formerly known as [Barr Labs] is known for its involvement in an industry changing federal court decision called United States v. Barr Laboratories which brought reform to both Barr and the generic drug industry. In 2001, Barr again made headlines by successfully challenging Eli Lily's Prozac patents in court for Lily's multi-bllion dollar drug Prozac.

Additional Information: Barr Pharmaceutical Corporate Website